FDA to Review Efgartigimod for Generalized Myasthenia Gravis
Efgartigimod, an Fc receptor antagonist, reduces disease-causing immunoglobulin G (IgG) antibodies and blocks the IgG recycling process.
Efgartigimod, an Fc receptor antagonist, reduces disease-causing immunoglobulin G (IgG) antibodies and blocks the IgG recycling process.
Cerliponase alfa demonstrates a slower rate of decline of developmental skills in patients with CLN2 disease compared to a natural history cohort.
Infection can occur when Naegleria fowleri-contaminated water enters body through the nose.
Naegleria fowleri can get into the brain when contaminated water enters the nose.
The FDA has approved Enspryng (satralizumab-mwge; Genentech) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Annual recurrence rate reduced with vitamin D, calcium supplementation versus observation.
Data scant on exposure to gadolinium-based contrast agents for those with acute kidney injury, risk for CKD.
Higher doses of deutetrabenazine appear to be safe and well tolerated in patients with Huntington disease who may require them to adequately control chorea, according to a recently published post-hoc analysis.
The FDA has approved UpliznaTM (inebilizumab-cdon; Viela Bio) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
The FDA has granted Orphan Drug designation to PN-1007 (PPSGG; Polyneuron Pharmaceuticals) for the treatment of anti-myelin-associated glycoprotein (MAG) neuropathy.